HIPAA Changes Guidance Rules to Help Tackle COVID-19 Pandemic
The goal is to help public health departments collect information vital to their efforts to contain the COVID-19 pandemic.
All articles by John Schieszer, MA
Fewer Systematic Biopsy Cores May Not Lower PCa Detection Rate
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
Prostate Cancer Immunotherapy Alone Is Not Enough
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
Metformin Found Not to Prevent Prostate Cancer
A study looking at the effect of genetic variations on the pharmacologic activity of metformin found that use of the drug was associated with an increased risk of prostate cancer overall and of high-grade prostate cancer.
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
-
Loading...
-
Loading...
Next post in Prostate Cancer
